<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of relapsed or refractory mantle cell lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of relapsed or refractory mantle cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of relapsed or refractory mantle cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mantle cell lymphoma (MCL) is a B cell non-Hodgkin lymphoma that can have a variable course. Although some patients may survive untreated for years, most patients experience a more aggressive course. MCL is often responsive to initial therapy, but some patients do not achieve a complete response (CR) with initial treatment (primary refractory disease), and others experience one or more relapses after achieving CR.</p><p>Conventional chemoimmunotherapy has limited, transient benefit for relapsed or refractory (r/r) MCL due to rapid development of chemotherapy resistance. Management of r/r MCL has improved with the availability of Bruton tyrosine kinase inhibitors (BTKis) and chimeric antigen receptor (CAR)-T cell therapy, which offer greater efficacy with acceptable toxicity. Nevertheless, therapy for MCL is generally not curative, and most patients will experience multiple relapses. Enrollment in a clinical trial is encouraged.</p><p>Treatment of r/r MCL is discussed here. </p><p>Initial treatment of MCL and clinical and pathologic features are discussed separately. (See  <a class="medical medical_review" href="/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management"</a> and  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p class="headingAnchor" id="H276217099"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Relapsed or refractory (r/r) MCL refers to disease that was not cured by initial treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed MCL</strong> – Recurrence of MCL after achieving a complete response (CR). The interval from completion of therapy to recurrence (ie, the duration of CR) has prognostic impact.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory MCL</strong> – Failure to achieve a CR with initial induction therapy is called primary refractory MCL or primary induction failure. Patients with refractory MCL generally have less favorable outcomes than patients with relapsed disease. </p><p></p><p>Prognosis generally declines with each subsequent relapse. The goals of care for r/r MCL are influenced by the number of prior relapses, previous treatments, age, fitness, and patient preference. Prognostic factors for r/r MCL are discussed below. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H3529814514"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H4051783410"><span class="h2">Clinical and laboratory</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical </strong>– The presence of B symptoms and lymph node, organ involvement, or other extranodal disease should be documented by history and physical examination. (See  <a class="medical medical_review" href="/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Complete blood count (CBC) with leukocyte differential count</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistries</strong> – Serum electrolytes, glucose, blood urea nitrogen (BUN) and creatinine, calcium, uric acid, and liver function tests, including lactate dehydrogenase (LDH)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infectious</strong> – Human immunodeficiency virus (HIV) and hepatitis B virus testing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy testing</strong> – If appropriate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac</strong> – Electrocardiogram (ECG), echocardiogram, and/or radionuclide ventriculogram (RVG), as clinically indicated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Endoscopy/colonoscopy, contrast-enhanced computed tomography (CT), or other clinical testing should be performed, if clinically indicated, to evaluate potential extranodal involvement.</p><p></p><p class="headingAnchor" id="H1814139364"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Pathologic confirmation is generally required to diagnose relapsed or refractory (r/r) MCL, but the need for a biopsy may vary with the clinical setting:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed MCL</strong> – A biopsy is required to confirm the diagnosis and to exclude other conditions for a suspected first relapse of MCL. </p><p></p><p class="bulletIndent1">A repeat biopsy may not be needed to confirm subsequent relapses if the diagnosis is supported by clinical and imaging data. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory MCL</strong> – A repeat biopsy is preferred to confirm the diagnosis of primary refractory MCL and to exclude a reactive, post-treatment inflammatory response. However, a biopsy may not be required if positron emission tomography (PET)/CT revealed a clear progression of the size and metabolic activity of a disease site. </p><p></p><p class="bulletIndent1">If a biopsy is not performed in this setting, the morphology, immunophenotype, and cytogenetic/molecular features of the initial biopsy specimen should be reviewed to ensure that MCL was correctly diagnosed. </p><p></p><p>Pathologic and genetic features for a diagnosis of MCL are described separately. (See  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2183551057"><span class="h2">Restaging</span><span class="headingEndMark"> — </span>Restaging is based on clinical evaluation, laboratory studies, and PET/CT, according to the Lugano criteria  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – PET/CT is scored using the five-point (Deauville) scale  (<a class="graphic graphic_table graphicRef108973" href="/d/graphic/108973.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow examination </strong>– Bone marrow aspirate and biopsy are generally not required for restaging r/r MCL because PET is a good predictor for marrow involvement. </p><p></p><p class="bulletIndent1">If bone marrow examination<strong> </strong>is performed, it should be analyzed by microscopy, cytogenetics (using fluorescence in situ hybridization [FISH] or Giemsa-stained chromosome analysis), and molecular studies, as described separately. (See  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis", section on 'Pathology'</a>.)</p><p></p><p class="headingAnchor" id="H1426391753"><span class="h2">Fitness</span><span class="headingEndMark"> — </span>We assess and classify fitness according to functional status and comorbid conditions. Age, per se, is not a measure of fitness. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional status</strong> – A fitness assessment should include performance status  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – Risk for bleeding, thromboembolism, cardiac conditions, liver disease, and other comorbid conditions may affect a patient's suitability for various agents used to treat r/r MCL, as described in the sections that follow.</p><p></p><p>Fitness should be reassessed at the time of each relapse, as it may change with subsequent relapses and/or prior treatments.</p><p class="headingAnchor" id="H1187093531"><span class="h1">FIRST RELAPSE OR PRIMARY REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>The choice of salvage therapy for first relapse or primary refractory MCL is guided by whether the patient was previously treated with a Bruton tyrosine kinase inhibitor (BTKi).</p><p>Treatment for frail patients is discussed below. (See <a class="local">'Frail patients'</a> below.)</p><p class="headingAnchor" id="H175006493"><span class="h2">No prior Bruton tyrosine kinase inhibitor</span><span class="headingEndMark"> — </span>For first relapse of MCL or primary refractory MCL in a BTKi-naïve patient, we suggest salvage therapy using either <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> rather than <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> or other treatments. This suggestion is based on the more favorable balance of outcomes and toxicity with acalabrutinib or zanubrutinib compared with other treatments. </p><p>When the second-generation BTKis, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a>, are not available, treatment with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> is acceptable. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – BTKis should be avoided in patients with a high risk for bleeding (eg, patients receiving anticoagulants or with severe thrombocytopenia) or cardiovascular disorders (eg, dysrhythmias, uncontrolled hypertension). </p><p></p><p class="bulletIndent1">We generally administer BTKis as single agents rather than combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or other drugs.</p><p></p><p class="bulletIndent1">Selection of salvage therapy for patients who are not candidates for BTKi treatment is discussed below. (See <a class="local">'Second relapse'</a> below.)</p><p></p><p class="bulletIndent1">All BTKis may interact with CYP3A inhibitors or inducers  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) and may require dose modification, as described in the package inserts. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acalabrutinib</strong> – <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> is taken 100 mg twice daily by mouth. </p><p></p><p class="bulletIndent2">The oral capsule, but not the oral tablet, is affected by coadministration with acid-reducing medications (eg, proton pump inhibitors), as described in the product label. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ibrutinib</strong> – <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is taken 560 mg (four 140 mg capsules) by mouth once daily. </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> should not be used in patients with baseline hepatic impairment. Dose modifications for toxicity are described in the package insert.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Zanubrutinib</strong> – <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">Zanubrutinib</a> is taken 320 mg once daily by mouth (or 160 mg twice daily by mouth), swallowed whole with water and with or without food. Patients should be advised to not open, break, or chew capsules.</p><p></p><p class="bulletIndent1">We repeat positron emission tomography (PET) after two to four treatment cycles to assess the initial response to therapy and proceed according to the findings  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 5</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete response or partial response</strong> – Treatment continues until there is disease progression or drug intolerance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable disease or progressive disease</strong> – Treat as per second relapse. (See <a class="local">'Second relapse'</a> below.)</p><p></p><p class="bulletIndent1">Abrupt BTKi discontinuation has been associated with rapid disease progression [<a href="#rid1">1</a>]. If chimeric antigen receptor (CAR)-T cell therapy is being considered for disease progression while using a BTKi, it is important to either continue the BTKi or switch to another therapy prior to leukapheresis for harvesting T cells. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are approved by the US Food and Drug Administration (FDA) for treatment of relapsed or refractory (r/r) MCL after ≥1 prior therapy; neither agent is approved by the European Medicines Agency (EMA) for r/r MCL.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is approved by the EMA for r/r MCL. Ibrutinib was FDA approved for treatment of r/r MCL after ≥1 prior treatment, but the manufacturer requested withdrawal of approval for that indication (based on results from a phase 3 trial in patients with previously untreated MCL [<a href="#rid2">2</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – The most common, serious adverse effects (AEs) associated with BTKi therapy are bleeding, arrhythmias, opportunistic infections, and second primary malignancies; other toxicities include cytopenias, headache, upper respiratory tract infection, and diarrhea. Treatment interruption, dose reduction, or discontinuation may be required to manage toxicity.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> was associated with more AEs than <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> in a randomized trial for Waldenström macroglobulinemia [<a href="#rid3">3</a>]. For patients treated with ibrutinib, serum creatinine should be monitored, and patients should be encouraged to maintain hydration, as ibrutinib has been associated with serious and potentially fatal renal toxicity; acute renal failure developed in 3 percent of 111 patients treated with ibrutinib for MCL [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a>, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are all effective for r/r MCL, but they have not been directly compared in randomized studies in this setting. </p><p></p><p class="bulletIndent1">In a real-world study, BTKis were used in more than one-half of 933 patients with r/r MCL; <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> were other agents that were used [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1">Studies of individual BTKis for r/r MCL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acalabrutinib</strong> – In a study of 124 patients with r/r MCL, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> was associated with a 72 percent 24-month overall survival (OS), 49 percent 24-month progression-free survival (PFS), and 81 percent overall response rate (ORR; including a 40 percent complete response [CR]) [<a href="#rid6">6,7</a>]. Grade ≥3 AEs included infections (15 percent), anemia (10 percent), and neutropenia (10 percent). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Zanubrutinib</strong> – In a study of 86 patients with r/r MCL, <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> was associated with a 76 percent 12-month PFS and 22-month median PFS [<a href="#rid8">8</a>]. The most common grade ≥3 AEs were neutropenia (20 percent) and lung infection/pneumonia (9 percent). Major bleeding was reported in three patients, and there were no reports of atrial fibrillation. </p><p></p><p class="bulletIndent2">In an earlier study that included 37 patients with r/r MCL (among 48 enrolled patients), the 12-month OS was 87 percent, 12-month PFS was 83 percent, and ORR was 84 percent (including a 25 percent CR) [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ibrutinib</strong> – <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is effective as monotherapy and when combined with other agents for treating r/r MCL. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monotherapy</strong> – Pooled analysis of three studies (370 patients with r/r MCL) reported that <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> for first relapse of MCL was associated with a 68 percent two-year OS, 57 percent two-year PFS, and 66 percent ORR (including a 20 percent CR) [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A real-world analysis of 211 patients treated with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> for first relapse of MCL was associated with a 24-month median OS, 18-month median PFS, and 69 percent ORR (including 27 percent CR); the inferior survival outcomes compared with the pooled analysis (above) may be related to older age and worse performance status [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> monotherapy was associated with a 47 percent 24-month OS, 31 percent 24-month PFS, and 67 percent ORR (including a 23 percent CR) in a multicenter study of 111 patients with r/r MCL (who had a median of three prior therapies) [<a href="#rid4">4,12</a>]. </p><p></p><p class="bulletIndent3">In a phase 3 trial (RAY) of 280 patients with r/r MCL, compared with <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> achieved superior PFS and a trend toward a better OS, but there were more grade ≥3 bleeding events (9 versus 5 percent) and more atrial fibrillation (5 versus 1 percent) [<a href="#rid13">13,14</a>]. Ibrutinib was associated with better survival than bendamustine-based treatment for patients who had an initial treatment response &lt;24 months, but outcomes did not differ between treatments for patients whose first remission was ≥24 months in a retrospective study [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Combination therapy</strong> – <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> has been combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> for treatment of r/r MCL. </p><p></p><p class="bulletIndent3">A phase 2 study reported that <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> was associated with an 88 percent ORR (including a 44 percent CR) in 50 adults with r/r MCL who had a median of three prior therapies [<a href="#rid16">16</a>]. In a study that included 50 patients with r/r MCL (a median of three prior therapies), ibrutinib plus rituximab was associated with a 43-month median PFS and 58 percent CR [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent3">Treatment with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> in 23 patients with r/r MCL reported a 42 percent CR by PET at 16 weeks [<a href="#rid18">18</a>]. One-half of the patients had mutations of <em>TP53</em> and 75 percent had a high-risk prognostic score. Grade ≥3 AEs included diarrhea (71 percent), neutropenia (33 percent), thrombocytopenia (17 percent), and anemia (12 percent).</p><p></p><p class="headingAnchor" id="H2193946641"><span class="h2">Prior Bruton tyrosine kinase inhibitor treatment</span><span class="headingEndMark"> — </span>Management for patients who previously received a BTKi is guided by the following clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remote Bruton tyrosine kinase inhibitor therapy</strong> – If BTKi use was remote (eg, relapse &gt;1 year since exposure), we suggest salvage therapy with a BTKi, as discussed above. (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other patients</strong> – For primary refractory MCL or relapse ≤1 year since last exposure, we suggest <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> based on its efficacy and modest toxicity. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is approved by the EMA for treatment of r/r MCL, and it is approved by the FDA for treatment of adults with r/r MCL after two prior therapies, one of which included <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. Lenalidomide has boxed warnings regarding embryo-fetal toxicity, hematologic toxicity, and venous thromboembolism. In the United States, lenalidomide is subject to the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.revlimid.com%2F&amp;token=gHgfAPQIBJZBPDYSeLaRCkU%2F8AD7eCjUze1DK%2FbZMI5%2Bwfbp8CZvmmuZo20rc1mo&amp;TOPIC_ID=4735" target="_blank">RevAssist program</a> to minimize the potential for pregnancy and associated disability since birth.</p><p></p><p class="bulletIndent1">We consider CAR-T cell therapy (see <a class="local">'Medically fit'</a> below), <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> (see <a class="local">'Less fit'</a> below), and <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> (see <a class="local">'Venetoclax'</a> below) acceptable in this setting, but they lack regulatory approval for first relapse or primary refractory disease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenalidomide</strong><strong> administration</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is given 25 mg by mouth on days 1 to 21 of 28-day cycles. </p><p></p><p class="bulletIndent2">We repeat PET after two to four cycles and continue treatment for patients with CR or partial response (PR)  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 5</a>). For patients with less than PR, we treat as per second relapse. (See <a class="local">'Second relapse'</a> below.)</p><p></p><p class="bulletIndent2">Treatment should continue until disease progression or drug intolerance, which generally occurs within one year. </p><p></p><p class="bulletIndent2">If <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is added to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, it is given by infusion at 375 mg/m<sup>2</sup> on day 1 of each treatment cycle for six months.</p><p></p><p class="bulletIndent2">Antithrombotic prophylaxis should be given according to the patient's underlying risk of venous and arterial thromboembolism. Our approach to prophylaxis for patients receiving <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> for r/r MCL is like that applied to patients with multiple myeloma, as discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is associated with an increased risk for arterial and venous thromboembolism, cytopenias, and embryo-fetal toxicity.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> may also be associated with infusion reactions, reactivation of hepatitis B, and rare cases of progressive multifocal leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Incorporation of rituximab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a>, with or without <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, is effective and well tolerated for the treatment of r/r MCL. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monotherapy</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> achieved better outcomes than the investigator's choice of therapy in the randomized MCL-002/SPRINT trial of 254 patients with r/r MCL who were ineligible for intensive chemotherapy or hematopoietic cell transplantation [<a href="#rid19">19</a>]. Lenalidomide achieved a superior PFS (nine versus five months; hazard ratio [HR] 0.61 [95% CI 0.44-0.84]) among 254 patients who were randomly assigned (2:1) to either lenalidomide or the investigator's choice of monotherapy (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, or <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>). The most common grade ≥3 AEs were neutropenia (73 percent with lenalidomide versus 34 percent) and thrombocytopenia (18 versus 28 percent). </p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> was associated with a 19-month median OS, 4-month median PFS, 28 percent ORR (including an 8 percent CR), and 17-month duration of response (DOR) in an earlier study (MCL-001; EMERGE) of 134 patients with r/r MCL who were previously treated with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid20">20</a>]. Other studies reported similar outcomes with lenalidomide for r/r MCL [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Lenalidomide</strong><strong> plus </strong><strong>rituximab</strong></p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> was associated with a 24-month median OS, 11-month median PFS, and 57 percent ORR (including a 36 percent CR) with a 19-month median DOR in a study of 52 patients with r/r MCL [<a href="#rid23">23</a>]. Grade ≥3 AEs included neutropenia (66 percent) and thrombocytopenia (23 percent). Lenalidomide, rituximab, plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in 50 patients with r/r MCL reported a 76 percent ORR (including a 56 percent CR) [<a href="#rid24">24</a>]. </p><p></p><p class="headingAnchor" id="H730430758"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>We monitor the patient clinically for disease progression during and after salvage therapy.</p><p>We generally schedule follow-up visits every three to six months for five years and then yearly, or as clinically indicated. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical/laboratory evaluation</strong> – Visits include clinical evaluation and screening laboratory studies, including complete blood count (CBC) with leukocyte differential count and serum chemistries, including lactate dehydrogenase (LDH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Imaging should be performed as clinically indicated, but to lessen radiation exposure, we do not perform routine (ie, scheduled) positron emission tomography (PET) and/or CT. </p><p></p><p>If there is clinical evidence of relapse, we restage with PET/CT and begin management for second relapse. (See <a class="local">'Second relapse'</a> below.) </p><p class="headingAnchor" id="H2016793823"><span class="h1">SECOND RELAPSE</span><span class="headingEndMark"> — </span>Most patients who are treated for primary refractory MCL or first relapse of MCL will again relapse within one to two years. Diagnosis of second relapse is discussed above. (See <a class="local">'Diagnosis'</a> above.) </p><p>Management of second relapse of MCL is guided by medical fitness. </p><p class="headingAnchor" id="H1444882755"><span class="h2">Medically fit</span><span class="headingEndMark"> — </span>For fit patients with second relapse of MCL and fit patients who did not achieve a complete response (CR) with initial salvage therapy, we suggest chimeric antigen receptor (CAR)-T cell therapy using <a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">brexucabtagene autoleucel</a> rather than other treatments. </p><p><a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">Brexucabtagene autoleucel</a> (formerly KTE-X19) is a CD19-directed CAR-T cell therapy that received accelerated approval by the US Food and Drug Administration (FDA) for treatment of relapsed or refractory (r/r) MCL.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – A single dose of 2 x 10<sup>6</sup> CAR-positive viable T cells/kg body weight (maximum 2 x 10<sup>8</sup> cells) is administered in a health care facility that is certified for its use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Brexucabtagene is associated with potentially fatal cytokine release syndrome (CRS); neurologic events; and opportunistic infections, including disseminated fungal infections (eg, <em>Candida</em>, <em>Aspergillus</em>) and viral reactivation (eg, human herpes virus-6 [HHV-6] encephalitis and John Cunningham [JC] virus-associated progressive multifocal leukoencephalopathy).</p><p></p><p class="bulletIndent1">Diagnosis and management of CRS and neurologic events are discussed separately. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a> and  <a class="medical medical_review" href="/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Brexucabtagene was associated with an 83 percent estimated 12-month overall survival (OS), 61 percent 12-month progression-free survival (PFS), and 93 percent overall response rate (ORR; including a 67 percent CR) among 60 patients with r/r MCL (a median of 65 years) in a multicenter study [<a href="#rid25">25</a>]. All patients had been previously treated with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> and/or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, 81 percent had received ≥3 prior lines of treatment, one-third had blastoid or pleomorphic histology, and one-sixth of evaluable patients had <em>TP53</em> mutation. The CAR-T cell product was successfully manufactured in 96 percent of patients, with a median of 16 days from leukapheresis to delivery. Grade ≥3 adverse effects (AEs) occurred in all patients, including cytopenias (94 percent) and infections (32 percent, including two fatal events). Grade ≥3 CRS occurred in 15 percent of patients (which required <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> in 59 percent and glucocorticoids in 22 percent) and neurologic events in 31 percent; none of these events was fatal.</p><p></p><p>We monitor the patient for relapse after completing CAR-T cell therapy, as described above. (See <a class="local">'Monitoring'</a> above.)</p><p><a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">Brexucabtagene autoleucel</a> is approved by the FDA as third-line therapy for patients with r/r MCL after prior treatment with chemoimmunotherapy and a Bruton tyrosine kinase inhibitor (BTKi). </p><p><a class="drug drug_general" data-topicid="130728" href="/d/drug information/130728.html" rel="external">Lisocabtagene maraleucel</a> (another CD19-directed CAR-T cell product) has similar activity. Treatment of 269 patients with various r/r B cell lymphomas with adverse features (but not including any patients with r/r MCL) was associated with a 73 percent ORR (including 53 percent CR) and AEs (2 percent grade ≥3 CRS; 20 percent grade ≥3 neurologic events) to <a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">brexucabtagene autoleucel</a> [<a href="#rid26">26</a>]. Lisocabtagene maraleucel is not approved in this setting.  </p><p class="headingAnchor" id="H2474327635"><span class="h2">Less fit</span><span class="headingEndMark"> — </span>For patients with second relapse of MCL who are not medically fit for CAR-T cell therapy, we suggest <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> rather than other treatments.</p><p>Most patients with second relapse of MCL were previously treated with a BTKi, either with initial treatment or for first relapse/primary refractory disease. <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> noncovalently binds BTK distant from the C481 residue, which is the binding site for other BTKis and the most common site for mutations associated with BTKi resistance [<a href="#rid27">27</a>]. </p><p><a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> is approved by the FDA for treatment of r/r MCL after ≥2 lines of systemic therapy, including a BTKi. </p><p>Where <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> is not available and for patients with a contraindication to BTKi treatment, alternative salvage therapy is discussed below. (See <a class="local">'Subsequent relapses'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> 200 mg is taken once daily by mouth and swallowed whole with water (with or without food). Strong CYP3A inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) should be avoided. If treatment with a strong or moderate CYP3A inducer is unavoidable, the dose of pirtobrutinib should be increased.</p><p></p><p class="bulletIndent1">We repeat positron emission tomography (PET) after two to four treatment cycles to assess the initial response to therapy  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 5</a>). Further management is guided by the PET findings: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete response or partial response</strong> – Treatment continues until disease progression or drug intolerance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable disease or progressive disease</strong> – Treat as per third or later relapse. (See <a class="local">'Subsequent relapses'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – As with other BTKis, <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> is associated with cytopenias, infections, hemorrhage, and atrial fibrillation/flutter. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For 120 patients with r/r MCL who were previously treated with a BTKi (among 323 patients with various r/r B cell malignancies), <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> was associated with a 50 percent ORR (including a 13 percent CR) with an eight-month duration of response (DOR) [<a href="#rid28">28</a>]. The most common grade ≥3 AE was neutropenia (in 10 percent); other AEs included fatigue, diarrhea, and bruising.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 1 to 2 study of <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> (BRUIN) that included 90 patients with r/r MCL (who received a median three prior lines of therapy) reported a 58 percent ORR (including a 20 percent CR) and a 22-month median DOR [<a href="#rid29">29</a>]. Grade ≥3 AEs included hemorrhage (4 percent) and atrial fibrillation/flutter (1 percent).</p><p></p><p class="headingAnchor" id="H1304504173"><span class="h1">SUBSEQUENT RELAPSES</span><span class="headingEndMark"> — </span>Patients who experience a third or later relapse of MCL generally have a grim prognosis. Successive treatment with various agents is often the most effective method for symptom management, disease control, and prolongation of survival. Potential treatment options are described below. (See <a class="local">'Salvage therapy for third or later relapse'</a> below.)</p><p>Some patients choose palliation of symptoms rather than treatments to control the disease in this setting; management options are described below. (See <a class="local">'Frail patients'</a> below.)</p><p>Allogeneic hematopoietic cell transplantation (HCT) is the only treatment that has been proven to achieve a durable response and potential cure in this setting. For medically fit patients with relapsed or refractory (r/r) MCL that responds adequately to salvage therapy, consolidation with allogeneic HCT is discussed below. (See <a class="local">'Consolidation with allogeneic hematopoietic cell transplantation'</a> below.)</p><p class="headingAnchor" id="H2550800364"><span class="h2">Salvage therapy for third or later relapse</span><span class="headingEndMark"> — </span>Selection of salvage therapy for third or later relapse is guided by previous therapy, fitness, comorbidities, and patient preferences. </p><p>There is no consensus in this setting. Our approach is informed by prior treatments, as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>No prior treatment with </strong><strong>pirtobrutinib</strong><strong> or </strong><strong>lenalidomide</strong><strong> </strong>– If not previously given, we favor treatment with <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pirtobrutinib</strong><strong> </strong>– <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> is contraindicated in patients with bleeding disorders and cardiac dysrhythmias, as discussed above. (See <a class="local">'Less fit'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> was associated with a 52 percent overall response rate (ORR; including a 13 percent complete response [CR]) with an eight-month duration of response (DOR) in 52 patients with r/r MCL who were previously treated with a Bruton tyrosine kinase inhibitor (BTKi) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenalidomide</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is associated with increased risk for arterial and venous thromboembolism, and antithrombotic prophylaxis should be given, as described above. (See <a class="local">'Prior Bruton tyrosine kinase inhibitor treatment'</a> above.)</p><p></p><p class="bulletIndent2">In the MCL-004 study, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> was associated with a 29 percent ORR and 20-week DOR among 58 patients who were previously treated with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>; 13 received lenalidomide monotherapy, 11 were treated with lenalidomide plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and 34 received lenalidomide plus other agents [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior treatment with </strong><strong>pirtobrutinib</strong><strong> and </strong><strong>lenalidomide</strong><strong> </strong>– Treatment options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venetoclax</strong><strong> </strong>– There are limited data regarding <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> therapy in patients with r/r MCL. Administration, toxicity, and outcomes with venetoclax-based therapy are presented below. (See <a class="local">'Venetoclax'</a> below.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is not approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) for treatment of r/r MCL. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bortezomib</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> has limited activity for r/r MCL. Administration, toxicity, and outcomes with bortezomib are presented below. (See <a class="local">'Bortezomib'</a> below.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> is approved by the FDA for treatment of r/r MCL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other approaches </strong>– Various treatments, including <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, combination chemotherapy, and radiation therapy have been used for multiply relapsed MCL and may be beneficial for selected patients, as described below. (See <a class="local">'Other systemic therapy'</a> below.)</p><p></p><p class="bulletIndent1">Outcomes for patients with r/r MCL who were previously treated with a BTKi are generally disappointing. Among 73 patients with r/r MCL who progressed after <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> therapy, treatment using various single agents (eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>) was associated with a six-month median overall survival (OS), two-month median progression-free survival (PFS), and 26 percent ORR (including a 7 percent CR) [<a href="#rid31">31</a>]. For 31 patients treated with various immunochemotherapy regimens after ibrutinib treatment, the median OS was eight months, and the ORR was 32 percent (including a 19 percent CR) with a six-month median DOR [<a href="#rid32">32</a>]. Another study of patients who progressed after ibrutinib reported 20 to 48 percent ORR (including 0 to 19 percent CR) [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H3106752709"><span class="h2">Response assessment</span><span class="headingEndMark"> — </span>We repeat positron emission tomography (PET) after two to four treatment cycles, assess response according to Lugano criteria  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 5</a>), and proceed according to the findings: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete response or partial response</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fit, younger (eg, ≤70 years) patients</strong> – For selected fit patients with CR or partial response (PR) after salvage therapy for third or later relapse, we consider transplantation as consolidation therapy. (See <a class="local">'Consolidation with allogeneic hematopoietic cell transplantation'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – Continue treatment until disease progression or drug intolerance, then switch to an alternate approach. (See <a class="local">'Salvage therapy for third or later relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable disease or progressive disease</strong> – Switch to an alternative salvage therapy or palliative management.</p><p></p><p class="headingAnchor" id="H38559925"><span class="h2">Consolidation with allogeneic hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Consolidation therapy using allogeneic HCT can be considered for transplant-eligible patients with a robust response to salvage therapy for multiply relapsed MCL. </p><p>Salvage therapy prior to allogeneic HCT is described above. (See <a class="local">'Subsequent relapses'</a> above.)</p><p>Allogeneic HCT is the only treatment that has been proven to achieve a durable response and potential cure for patients with multiply relapsed MCL, but it is associated with substantial toxicity and possible transplantation-associated mortality. The decision to pursue allogeneic HCT should be made after discussion with the patient, with due consideration of the potential benefits and toxicity. </p><p>We generally restrict allogeneic HCT for patients with r/r MCL who meet the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Third or later relapse</strong> – We consider allogeneic HCT <strong>only</strong> for patients who relapsed after receiving chimeric antigen receptor (CAR)-T cell therapy. (See <a class="local">'Medically fit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and fitness </strong>– Most institutions restrict allogeneic HCT to medically fit patients ≤70 years without major comorbid conditions. Some experts apply less stringent age and/or fitness criteria, given the grim prognosis in this setting.</p><p></p><p class="bulletIndent1">Details of eligibility for allogeneic HCT are discussed separately. (See  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to salvage therapy</strong> – Many experts reserve allogeneic HCT for patients who achieve CR to salvage therapy; some experts proceed to allogeneic HCT for patients with PR to salvage therapy.</p><p></p><p>Most experts favor nonmyeloablative (NMA) or reduced-intensity conditioning (RIC) rather than myeloablative conditioning (MAC) to reduce adverse effects (AEs) in this heavily pretreated population. Autologous HCT is not curative for r/r MCL, and it is not commonly employed in this setting. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Allogeneic HCT can provide robust and durable responses for patients with r/r MCL, but it is associated with substantial toxicity and possible transplantation-associated mortality. Outcomes with allogeneic HCT following CAR-T cell therapy are not yet available. It is difficult to draw conclusions about outcomes with HCT for r/r MCL because most studies are small and included heterogeneous patient populations (eg, transplantation after first, second, third, or later relapse), various conditioning regimens, and different graft sources. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 35 patients with r/r MCL who underwent RIC allogeneic HCT, the six-year OS was 53 percent, six-year PFS was 46 percent, and rates of treatment-related mortality (TRM) at 3 and 12 months were 0 and 9 percent, respectively [<a href="#rid34">34</a>]. Nearly two-thirds of patients were transplanted after achieving CR (including one-third who were in second CR). In a study of 33 patients who received RIC allogeneic HCT, outcomes after two years included 65 percent OS, 60 percent disease-free survival, 9 percent relapses, and 24 percent TRM [<a href="#rid35">35</a>]. None of the 13 patients who were transplanted in CR relapsed after a two-year observation. In another study, three-year OS and PFS were 86 and 82 percent, respectively, among 18 patients who received RIC allogeneic HCT for r/r MCL; 89 percent of patients had chemosensitive disease [<a href="#rid36">36</a>]. Other small studies of allogeneic HCT that included patients with r/r MCL have reported similar outcomes [<a href="#rid37">37-40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Toxicity is substantial, even with NMA conditioning regimens. Analysis of data from a transplant registry reported 17 to 25 percent nonrelapse mortality (NRM) among 133 patients who underwent RIC allogeneic HCT for r/r MCL [<a href="#rid41">41</a>]. </p><p></p><p>Disease status at transplantation was the only predictor of outcomes in a retrospective analysis of 70 patients; two-year OS was 53 percent for 35 patients transplanted in CR, compared with 20 percent in PR, and 15 percent with stable or progressive disease [<a href="#rid42">42</a>]. Response duration &gt;12 months after autologous HCT was associated with better outcomes with allogeneic HCT than earlier relapse or primary refractory disease [<a href="#rid43">43</a>]. Allogeneic HCT had similar activity in patients with r/r MCL with or without<em> TP53</em> abnormalities in a study of 42 patients [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H1135985196"><span class="h1">FRAIL PATIENTS</span><span class="headingEndMark"> — </span>For frail patients with relapsed or refractory MCL, the focus of management is symptom control.</p><p>The choice of management is influenced by the extent of symptoms, site(s) of relapse, and patient preference. Palliative management (eg, radiation therapy) and supportive care can provide temporary relief of symptoms but generally do not prolong survival. </p><p class="headingAnchor" id="H3909787689"><span class="h1">TREATMENTS</span></p><p class="headingAnchor" id="H1510330977"><span class="h2">Bruton tyrosine kinase inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acalabrutinib</strong><strong>, </strong><strong>ibrutinib</strong><strong>, </strong><strong>zanubrutinib</strong> – Administration, toxicity, outcomes, and approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are discussed above. (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pirtobrutinib</strong> – Administration, toxicity, outcomes, and approval by the FDA for <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> are discussed above. (See <a class="local">'Less fit'</a> above.)</p><p></p><p class="headingAnchor" id="H15359708"><span class="h2">Lenalidomide</span><span class="headingEndMark"> — </span>Administration, toxicity, outcomes, and approval by the FDA and the EMA for <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> are discussed above. (See <a class="local">'Prior Bruton tyrosine kinase inhibitor treatment'</a> above.)</p><p class="headingAnchor" id="H2152095441"><span class="h2">Other systemic therapy</span><span class="headingEndMark"> — </span>There are limited roles for other agents in patients with relapsed or refractory (r/r) MCL.</p><p class="headingAnchor" id="H3339404587"><span class="h3">Venetoclax</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is an orally administered B cell leukemia/lymphoma 2 (BCL2) inhibitor with modest activity in r/r MCL, but there are limited outcomes data in patients who received venetoclax after prior treatment with a Bruton tyrosine kinase inhibitor (BTKi).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is taken by mouth at doses up to 400 mg daily. Because of the risk of tumor lysis syndrome (TLS), we generally initiate treatment at 20 mg daily for one week and gradually escalate to the target dose of 400 mg daily over five weeks. However, more rapid dose escalation with inpatient monitoring may be considered for patients with highly proliferative disease [<a href="#rid45">45</a>]. </p><p></p><p class="bulletIndent1">Patients should be instructed to not chew, crush, or break tablets.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is not approved by the FDA or the EMA for r/r MCL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Adverse effects (AEs) include hematologic and gastrointestinal toxicity, increased risk for infections, and possible TLS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> has been used as monotherapy and in combination with other agents for r/r MCL. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study of 81 patients with r/r MCL reported that <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> monotherapy or venetoclax plus either a BTKi or a monoclonal antibody was associated with a 42 percent overall response rate (ORR), but the median progression-free survival (PFS) was only four months; 91 percent of patients had received prior BTKi treatment [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A series of 24 patients with r/r MCL (two-thirds of whom had progressed on a BTKi) reported that <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> salvage was associated with a 14-month overall survival (OS), eight-month PFS, and 50 percent ORR (including 21 percent CR); one-half of the patients received venetoclax monotherapy, while others received venetoclax in combination with chemotherapy, BTKi, or <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, and <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> in 15 patients (including r/r MCL and treatment-naïve MCL) reported 100 percent one-year OS, 93 percent one-year PFS, and 86 percent ORR (including undetectable measurable residual disease [MRD] in two-thirds of patients) [<a href="#rid48">48</a>]. Grade ≥3 neutropenia was reported in 20 percent of patients. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of 20 patients with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> after prior BTKi treatment reported a nine-month median OS, three-month median PFS, and 53 percent ORR (including an 18 percent complete response [CR]) with an eight-month median duration of response (DOR) [<a href="#rid49">49</a>]. There were three cases of grade 3 pneumonia, one case of grade 4 sepsis, and no cases of TLS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 1 study reported a 75 percent ORR (including a 21 percent CR) among 28 patients with MCL who had not received prior BTKi treatment [<a href="#rid50">50</a>]. </p><p></p><p class="headingAnchor" id="H3878640999"><span class="h3">Bortezomib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> is a proteasome inhibitor that is approved by the FDA for treatment of MCL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> is given 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day cycle, either as a 3 to 5 second bolus intravenous injection or by subcutaneous injection.</p><p></p><p class="bulletIndent1">A lower starting dose should be given for patients with moderate or severe hepatic impairment.</p><p></p><p class="bulletIndent1">Details of administration, monitoring, and management of toxicity are discussed separately. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> is associated with increased risk for infections (including reactivation of herpes zoster), neuropathy, cardiovascular events, and rare episodes of thrombotic microangiopathy, reversible posterior leukoencephalopathy syndrome, and progressive multifocal leukoencephalopathy.</p><p></p><p class="bulletIndent1">High rates of toxicity, including peripheral neuropathy, were reported when <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> is combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid51">51-53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase 2 study (PINNACLE) of 152 patients, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> was associated with a 33 percent ORR (including an 8 percent CR) and nine-month median DOR; the median time to progression was six months [<a href="#rid54">54</a>]. With longer follow-up, the median OS was 24 months; in patients with responding disease the median OS was 35 months [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase 3 trial for patients with r/r MCL, compared with CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> plus CHOP achieved a higher ORR (83 versus 48 percent), CR (35 versus 22 percent), and a longer median OS (36 versus 12 months) [<a href="#rid56">56</a>]. There was a higher incidence of grade ≥3 neutropenia (30 versus 20 percent), febrile neutropenia (20 versus 13 percent), and infections (39 versus 17 percent) in patients receiving bortezomib.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other studies have also reported outcomes with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> alone or combined with other agents, including <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and/or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid51">51,52,57-64</a>].</p><p></p><p class="headingAnchor" id="H315697241"><span class="h3">Temsirolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> is active for r/r MCL, but it was inferior to <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in a phase 3 trial, as described above. (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.) </p><p><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> 175 mg weekly for three weeks followed by either 75 or 25 mg weekly achieved superior PFS and ORR compared with the investigator's choice of therapy but was associated with substantial cytopenias and asthenia in a phase 3 trial [<a href="#rid65">65</a>]. Temsirolimus was associated with inferior PFS, a trend toward inferior OS, and worse toxicity when compared with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in another randomized trial, as described above [<a href="#rid13">13,14</a>]. (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.)</p><p><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> is approved by the EMA for the treatment of r/r MCL.</p><p class="headingAnchor" id="H1913111300"><span class="h3">Bendamustine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">Bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is efficacious and well tolerated in patients who were not previously treated with bendamustine. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Administration and toxicity of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> are described separately. (See  <a class="medical medical_review" href="/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management", section on 'Rituximab-bendamustine (R-B)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Following are studies with bendamustine-based therapy for r/r MCL. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">Bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> was superior to <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> plus rituximab in a phase 3 trial of 219 patients with r/r MCL or indolent lymphomas [<a href="#rid66">66</a>]. With a median follow-up of eight years, bendamustine plus rituximab achieved superior OS (110 versus 49 months; hazard ratio [HR] 0.64 [95% CI 0.45-0.91]), median PFS (34 versus 12 months; HR 0.54 [95% CI 0.38-0.72]), ORR (82 versus 51 percent), and CR (40 versus 17 percent). Subset analysis confirmed superior median PFS among the 47 patients with MCL (18 versus 5 months; HR 0.45 [95% CI 0.22-0.76]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, and <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> in patients with prior BTKi treatment reported an 83 percent ORR and 10-month median PFS, but more than one-half of patients required dose reductions due to toxicity [<a href="#rid67">67</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment using <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> in 45 patients (with a median of two prior therapies) reported 55 percent three-year OS, 82 percent ORR (including a 40 percent CR) with a median DOR of 1.6 years [<a href="#rid68">68</a>]. The ORR was 82 percent (including a 40 percent CR) with a median DOR of 1.6 years. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 2 study that included 18 patients with MCL reported that <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> were associated with a 78 percent ORR (including a 33 percent CR) [<a href="#rid69">69</a>]. The two-year OS was 60 percent and median PFS was 21 months.</p><p></p><p class="headingAnchor" id="H2178382651"><span class="h3">Other management</span><span class="headingEndMark"> — </span>Intensive chemotherapy has a limited role for management of r/r MCL, while monoclonal antibodies and radiation therapy can provide symptom relief in selected circumstances.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive chemotherapy </strong>– More intensive chemoimmunotherapy can achieve a response in patients with r/r MCL, but relapses are common, and toxicity can be substantial in heavily pretreated patients. As a result, we generally restrict such treatments to patients who require a bridge to control disease prior to allogeneic hematopoietic cell transplantation. </p><p></p><p class="bulletIndent1">Examples of regimens that have been used include R-CHOP (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) [<a href="#rid70">70</a>] or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, rituximab, plus a platin (eg, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [R-GDP] or <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [R-GemOx]) [<a href="#rid71">71,72</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> plus hyper-CVAD (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) alternating with rituximab plus <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> in 29 patients with r/r MCL reported an 11-month median failure-free survival and 93 percent ORR (including a 45 percent CR) [<a href="#rid73">73</a>]. Grade ≥3 AEs included neutropenia (74 percent), thrombocytopenia (63 percent), and febrile neutropenia (11 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibodies</strong> – CD20-directed monoclonal antibodies have modest activity as single agents for r/r MCL. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rituximab</strong> – A prospective study of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> monotherapy in 28 patients with r/r MCL reported 37 percent ORR, 14 percent CR, and 1.2-year median DOR [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obinutuzumab</strong> – A phase 2 study of the humanized anti-CD20 monoclonal antibody, <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, in 40 patients with r/r MCL or diffuse large B cell lymphoma reported 30 percent ORR (including 13 percent CR), with a 10-month median DOR; infusion reactions were seen in 75 percent and were severe in 8 percent [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – Radiation therapy can control local disease in patients with chemotherapy-refractory disease [<a href="#rid76">76-78</a>]. </p><p></p><p class="bulletIndent1">For older or less-fit patients with limited relapse (ie, stage I), radiation therapy alone can provide effective, temporary symptom relief.</p><p></p><p class="headingAnchor" id="H3890364973"><span class="h1">CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY</span><span class="headingEndMark"> — </span>Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy can achieve a robust response of relapsed or refractory (r/r) MCL in most patients, but it is associated with severe and potentially life-threatening toxicity.</p><p>Administration, toxicity, outcomes, and approval of CAR-T cell therapy for r/r MCL are presented above. (See <a class="local">'Medically fit'</a> above.)</p><p class="headingAnchor" id="H1127285257"><span class="h1">ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</span><span class="headingEndMark"> — </span>Allogeneic hematopoietic cell transplantation is generally restricted to fit patients ≤70 years who seek consolidation after a robust response to fourth-line therapy (ie, treatment for third or later relapse), as described above. (See <a class="local">'Consolidation with allogeneic hematopoietic cell transplantation'</a> above.)  </p><p class="headingAnchor" id="H3950481446"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Outcomes for patients with relapsed or refractory (r/r) MCL are associated with clinical characteristics (eg, duration of initial response, number of prior relapses) and certain pathologic features. </p><p>These prognostic factors apply for patients treated with Bruton tyrosine kinase inhibitors (BTKi) and chemoimmunotherapy, but it is uncertain at present if they apply to patients treated with immunotherapy, such as chimeric antigen receptor (CAR)-T cell therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of complete response</strong> – Early relapse (ie, &lt;24 months after initial treatment) was associated with inferior overall survival (OS) in retrospective studies of patients with r/r MCL [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Number of prior relapses</strong> – Disease progression after ≥2 lines of therapy is associated with a shortened time to subsequent relapse [<a href="#rid43">43,79,81</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MCL International Prognostic Index score</strong> – The MCL International Prognostic Index (MIPI) is a validated risk score based upon clinical variables at diagnosis, including age, performance status, lactate dehydrogenase (LDH), and white blood cell (WBC) count [<a href="#rid82">82-85</a>], that provides prognostic information for patients with r/r MCL, including patients treated with a BTKi [<a href="#rid10">10,81,86</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic features</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphology</strong> – The blastoid and pleomorphic histologic variants of MCL are associated with high-risk disease [<a href="#rid10">10,87</a>], while patients with transformed MCL are at highest risk for poor outcomes [<a href="#rid88">88</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proliferative rate</strong> – Ki67 immunostaining has been identified as a high-risk prognostic factor in r/r MCL [<a href="#rid8">8,16</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mutation status</strong> – <em>TP53</em> mutations, which are often associated with a high proliferative rate, were associated with inferior outcomes in multiple studies [<a href="#rid5">5,8,89-93</a>]. Mutations in <em>NOTCH1</em>,<em> NOTCH2</em>,<em> </em>and<em> KMT2D</em> and mutations or copy number loss of<em> CDKN2A </em>have also been associated with adverse prognosis<em> </em>[<a href="#rid89">89,90,94</a>].</p><p></p><p class="headingAnchor" id="H90400620"><span class="h1">CLINICAL TRIALS</span><span class="headingEndMark"> — </span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4735" target="_blank">www.clinicaltrials.gov</a>).</p><p class="headingAnchor" id="H2482573413"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122016.html" rel="external">"Society guideline links: Management of mantle cell lymphoma"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Mantle cell lymphoma (MCL) that relapses after prior complete response (CR) or does not achieve CR with initial therapy (primary refractory disease) carries an adverse prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – Clinical and laboratory evaluation, staging, fitness, and prognostic features are determined before treatment for relapsed or refractory (r/r) MCL. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Most cases of primary refractory MCL and first relapse require pathologic confirmation, but a biopsy may not be required for subsequent relapses, as discussed above. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First relapse or primary refractory MCL</strong> – Management is stratified according to prior treatment with a Bruton tyrosine kinase inhibitor (BTKi):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No prior Bruton tyrosine kinase inhibitor</strong> – For first relapse of MCL or primary refractory disease in a BTKi-naïve patient, we suggest <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> rather than other treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is acceptable when the other BTKis are not available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior Bruton tyrosine kinase inhibitor or contraindication to Bruton tyrosine kinase inhibitor</strong> – Guided by the interval since the last BTKi treatment (see <a class="local">'Prior Bruton tyrosine kinase inhibitor treatment'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients in whom prior BTKi was remote (&gt;1 year since exposure), we suggest salvage therapy with a BTKi (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For primary refractory MCL or relapse ≤1 year since exposure, we suggest <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Second relapse'</a> above.) </p><p></p><p class="bulletIndent3">Other acceptable options include chimeric antigen receptor (CAR)-T cell therapy, <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a>, or <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, but these lack regulatory approval for first relapse or primary refractory disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – The patient should be clinically monitored for disease progression/relapse during and after salvage therapy. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second relapse</strong> – For patients with second relapse of MCL, management is stratified by medical fitness:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically fit</strong> – For second relapse and for patients who did not achieve CR with salvage therapy, we suggest CAR-T cell therapy using <a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">brexucabtagene autoleucel</a> rather than other treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Medically fit'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Less fit</strong> – For patients who are not eligible for CAR-T cell therapy, we suggest <a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">pirtobrutinib</a> rather than other treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Less fit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent relapses</strong> – There is no consensus for subsequent relapses. (See <a class="local">'Subsequent relapses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Salvage therapy</strong> – Successive treatment with different agents is often most effective for symptom management, disease control, and prolongation of survival. (See <a class="local">'Salvage therapy for third or later relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consolidation therapy</strong> – Allogeneic hematopoietic cell transplantation (HCT) can be considered for consolidation therapy in selected transplant-eligible patients with a robust response to salvage therapy for multiply relapsed MCL. (See <a class="local">'Consolidation with allogeneic hematopoietic cell transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frail patients</strong> – Guided by symptoms, sites of relapse, and patient preference. (See <a class="local">'Frail patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments</strong> – Management and outcomes are discussed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bruton tyrosine kinase inhibitors</strong>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Acalabrutinib</strong><strong>, </strong><strong>ibrutinib</strong><strong>, </strong><strong>zanubrutinib</strong> (see <a class="local">'No prior Bruton tyrosine kinase inhibitor'</a> above).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pirtobrutinib</strong> (see <a class="local">'Subsequent relapses'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenalidomide</strong> (see <a class="local">'Prior Bruton tyrosine kinase inhibitor treatment'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venetoclax</strong> (see <a class="local">'Venetoclax'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bortezomib</strong> (see <a class="local">'Bortezomib'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Temsirolimus</strong> (see <a class="local">'Temsirolimus'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bendamustine</strong> (see <a class="local">'Bendamustine'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other approaches</strong> – More intensive combination chemotherapy, single-agent monoclonal antibodies, and radiation therapy have limited roles for management of r/r MCL. (See <a class="local">'Other management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chimeric antigen receptor</strong> <strong>T cell therapy</strong> – Administration, toxicity, and outcomes with CAR-T cell therapy are discussed above. (See <a class="local">'Medically fit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic hematopoietic cell transplantation</strong> – Roles for allogeneic HCT are discussed above. (See <a class="local">'Allogeneic hematopoietic cell transplantation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bond DA, Martin P, Maddocks KJ. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med 2022; 386:2482.</a></li><li><a class="nounderline abstract_t">Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136:2038.</a></li><li><a class="nounderline abstract_t">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507.</a></li><li><a class="nounderline abstract_t">Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 2022; 6:4122.</a></li><li><a class="nounderline abstract_t">Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018; 391:659.</a></li><li><a class="nounderline abstract_t">Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019; 33:2762.</a></li><li><a class="nounderline abstract_t">Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clin Cancer Res 2020; 26:4216.</a></li><li><a class="nounderline abstract_t">Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021; 5:2577.</a></li><li><a class="nounderline abstract_t">Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 2017; 179:430.</a></li><li><a class="nounderline abstract_t">McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021; 193:290.</a></li><li><a class="nounderline abstract_t">Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126:739.</a></li><li><a class="nounderline abstract_t">Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32:1799.</a></li><li><a class="nounderline abstract_t">Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387:770.</a></li><li><a class="nounderline abstract_t">Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 2021; 35:787.</a></li><li><a class="nounderline abstract_t">Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016; 17:48.</a></li><li><a class="nounderline abstract_t">Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018; 182:404.</a></li><li><a class="nounderline abstract_t">Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med 2018; 378:1211.</a></li><li><a class="nounderline abstract_t">Trněný M, Lamy T, Walewski J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol 2016; 17:319.</a></li><li><a class="nounderline abstract_t">Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31:3688.</a></li><li><a class="nounderline abstract_t">Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145:344.</a></li><li><a class="nounderline abstract_t">Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24:2892.</a></li><li><a class="nounderline abstract_t">Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13:716.</a></li><li><a class="nounderline abstract_t">Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol 2018; 5:e109.</a></li><li><a class="nounderline abstract_t">Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020; 382:1331.</a></li><li><a class="nounderline abstract_t">Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839.</a></li><li><a class="nounderline abstract_t">Wang E, Mi X, Thompson MC, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med 2022; 386:735.</a></li><li><a class="nounderline abstract_t">Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 2021; 397:892.</a></li><li><a class="nounderline abstract_t">Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol 2023; 41:3988.</a></li><li><a class="nounderline abstract_t">Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 2017; 10:171.</a></li><li><a class="nounderline abstract_t">Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016; 127:1559.</a></li><li><a class="nounderline abstract_t">Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 2015; 26:1175.</a></li><li><a class="nounderline abstract_t">Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol 2018; 181:306.</a></li><li><a class="nounderline abstract_t">Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113:4144.</a></li><li><a class="nounderline abstract_t">Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535.</a></li><li><a class="nounderline abstract_t">Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21:4407.</a></li><li><a class="nounderline abstract_t">Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865.</a></li><li><a class="nounderline abstract_t">Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.</a></li><li><a class="nounderline abstract_t">Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21:2316.</a></li><li><a class="nounderline abstract_t">Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418.</a></li><li><a class="nounderline abstract_t">Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014; 32:273.</a></li><li><a class="nounderline abstract_t">Le Gouill S, Kröger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23:2695.</a></li><li><a class="nounderline abstract_t">Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014; 25:1053.</a></li><li><a class="nounderline abstract_t">Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol 2019; 184:1006.</a></li><li><a class="nounderline abstract_t">Koenig KL, Huang Y, Dotson EK, et al. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv 2020; 4:4860.</a></li><li><a class="nounderline abstract_t">Sawalha Y, Goyal S, Switchenko JM, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv 2023; 7:2983.</a></li><li><a class="nounderline abstract_t">Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020; 95:623.</a></li><li><a class="nounderline abstract_t">Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood 2021; 137:877.</a></li><li><a class="nounderline abstract_t">Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019; 104:e68.</a></li><li><a class="nounderline abstract_t">Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 2017; 35:826.</a></li><li><a class="nounderline abstract_t">Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011; 117:2442.</a></li><li><a class="nounderline abstract_t">Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol 2010; 151:346.</a></li><li><a class="nounderline abstract_t">Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96:1008.</a></li><li><a class="nounderline abstract_t">Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867.</a></li><li><a class="nounderline abstract_t">Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20:520.</a></li><li><a class="nounderline abstract_t">Furtado M, Johnson R, Kruger A, et al. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol 2015; 168:55.</a></li><li><a class="nounderline abstract_t">Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667.</a></li><li><a class="nounderline abstract_t">O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676.</a></li><li><a class="nounderline abstract_t">Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24:2105.</a></li><li><a class="nounderline abstract_t">Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18:116.</a></li><li><a class="nounderline abstract_t">Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009; 146:652.</a></li><li><a class="nounderline abstract_t">O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009; 145:34.</a></li><li><a class="nounderline abstract_t">Srour SA, Lee HJ, Nomie K, et al. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. Br J Haematol 2018; 181:561.</a></li><li><a class="nounderline abstract_t">Morrison VA, Jung SH, Johnson J, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 2015; 56:958.</a></li><li><a class="nounderline abstract_t">Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822.</a></li><li><a class="nounderline abstract_t">Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016; 17:57.</a></li><li><a class="nounderline abstract_t">Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31:1442.</a></li><li><a class="nounderline abstract_t">Czuczman MS, Goy A, Lamonica D, et al. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 2015; 94:2025.</a></li><li><a class="nounderline abstract_t">Weide R, Hess G, Köppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48:1299.</a></li><li><a class="nounderline abstract_t">Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520.</a></li><li><a class="nounderline abstract_t">Morschhauser F, Depil S, Jourdan E, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18:370.</a></li><li><a class="nounderline abstract_t">Obrador-Hevia A, Serra-Sitjar M, Rodríguez J, et al. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. Br J Haematol 2016; 174:899.</a></li><li><a class="nounderline abstract_t">Wang M, Fayad L, Cabanillas F, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 2008; 113:2734.</a></li><li><a class="nounderline abstract_t">Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.</a></li><li><a class="nounderline abstract_t">Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31:2912.</a></li><li><a class="nounderline abstract_t">Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14:1555.</a></li><li><a class="nounderline abstract_t">Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006; 65:1185.</a></li><li><a class="nounderline abstract_t">Rossier C, Schick U, Miralbell R, et al. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e1.</a></li><li><a class="nounderline abstract_t">Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol 2019; 185:940.</a></li><li><a class="nounderline abstract_t">Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv 2021; 5:5179.</a></li><li><a class="nounderline abstract_t">Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J 2019; 9:50.</a></li><li><a class="nounderline abstract_t">Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558.</a></li><li><a class="nounderline abstract_t">Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014; 32:1338.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115:1530.</a></li><li><a class="nounderline abstract_t">Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29:3023.</a></li><li><a class="nounderline abstract_t">Jeon YW, Yoon S, Min GJ, et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med 2019; 8:6860.</a></li><li><a class="nounderline abstract_t">Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 2018; 132:2722.</a></li><li><a class="nounderline abstract_t">Jain P, Zhang S, Kanagal-Shamanna R, et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 2020; 4:1038.</a></li><li><a class="nounderline abstract_t">Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 2015; 126:604.</a></li><li><a class="nounderline abstract_t">Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica 2020; 105:1604.</a></li><li><a class="nounderline abstract_t">Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017; 130:1903.</a></li><li><a class="nounderline abstract_t">Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 2020; 136:1419.</a></li><li><a class="nounderline abstract_t">Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019; 104:e211.</a></li><li><a class="nounderline abstract_t">Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119:1963.</a></li></ol></div><div id="topicVersionRevision">Topic 4735 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33799484" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35657079" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32731259" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782157" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35561314" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241979" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558766" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32461234" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34152395" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28832957" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620106" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26059948" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572505" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26673811" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32782382" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26640039" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29785709" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590547" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26899778" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002500" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19245430" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030098" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677155" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396091" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242358" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888407" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35196427" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676628" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37192437" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096668" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764355" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Postibrutinib outcomes in patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712454" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29359797" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168784" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304387" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645431" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304395" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896000" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597807" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342784" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344210" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440229" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585719" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537212" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031541" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36809796" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32239765" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33181832" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30190341" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28095146" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048792" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880120" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21486866" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17001068" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19074748" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25146720" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613697" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613699" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606971" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971665" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624539" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220284" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369820" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996441" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581539" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26655425" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401442" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26411584" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613757" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873532" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of older patients with mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074972" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27220900" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973182" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637245" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835718" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504058" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Limited-stage mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682133" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398049" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Low-dose radiotherapy in indolent lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30407625" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34516611" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31110172" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962512" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687837" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032504" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21730271" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560165" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385481" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191807" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022239" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31537689" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819011" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584970" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442728" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210878" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
